From: Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis
Author & Year | Country | Year | Design | Source of data | STROBE criteria (met/applicable) | RT only No. (%) | CTX only No. (%) | RT-CTX No. (%) | Comments |
---|---|---|---|---|---|---|---|---|---|
Coleman 1987 [23] | UK | 1961-1980 | PBCS. | Cancer registry | 25/32 | (35–36) | (20–28) | (27–34) | Therapy data for M + F HL patients. Number NR. |
Hancock 1993 [24] | USA | 1961–1989 | Single institution cohort study | Computerized database and patient records | 24/31 | 383 (43) | 30 (3) | 341 (39) | Therapy data for M + F HL patients. 15% did not receive any treatment. |
Wolden 1998 [30] | USA | 1960-1995 | Single institution cohort study (HL Dx. ≤21y) | Computerized database and patient records | 22/31 | 144 (47) | 9 (3) | 154 (50) | Therapy data for female patients |
Wolden 2000 [37] | USA | 1960-1997 | Single institution retrospective review | Computerized database and patient records | 24/32 | 37 (57) | 1 (2) | 27 (41) | Therapy data for SBC patients. 27 patients received alkylating CTX. |
O'Brien 2010 [58] | USA | 1970-1990 | Single institution study of children | Retrospective chart review and patient questionnaires | 23/31 | 0 (0) | 0 (0) | 35 (100) | Therapy data for M + F pediatric HL patients. All received low-dose RT and alkylating CTX. |
van Leeuwen 1994 [25] | Netherlands | 1966-1986 | 2 institutions cohort study | Institutional registries and patient records | 22/30 | 552 (29) | 178 (9) | 1209 (62) | Therapy data for M + F HL patients. All SBC received RT. |
De Bruin 2009 [55] | Netherlands | 1965-1995 | 6 institutions cohort study (5y survivors) | Medical records, and physician questionnaires | 25/32 | 357 (31.8) | 80 (7.1) | 685 (61.1) | Therapy data for all HL female patients |
Mauch 1996 [26] | USA | 1969-1988 | 5 institutions cohort study | Institutional records | 25/31 | 489 (62) | 0 (0) | 305 (38) | Therapy data for M + F HL patients |
Ng 2002 [41] | USA | 1969–1997 | 4 institutions cohort study | Institutional records | 26/32 | 665 (69) | 0 (0) | 296 (31) | Therapy data for M + F HL patients |
Sankila 1996 [27] | Nordic countries | 1940-1987 | 5 Nordic PBCS (HL Dx. ≤20y) | National cancer registries | 21/31 | NR | NR | NR | All SBC patients received RT |
Metayer 2000 [36] | USA and Europe | 1935–1994 | 16 PBCS (HL Dx. ≤21y, 1-year survivors) | National cancer registries | 22/32 | NR | NR | NR | |
Hodgson 2007 [48] | USA and Europe | 1970-2001 | 13 PBCS (5-year survivors) | National cancer registries | 22/32 | 6461 (34) 145 (74) | 4398 (23) 26 (13) | 2847 (15) 36 (18) | First raw: therapy data for M + F HL patients. (27% with unknown treatment). Second raw:therapy data for SBC patients (28% with unknown treatment) |
Dores 2010 [57] | USA | 1973-2000 | 9 PBCS (5-year survivors, Dx. ≤35y) | 9 cancer registry areas of SEER | 22/32 | NR | NR | NR | All patients had RT |
Aisenberg 1997 [28] | USA | 1964-1984 | Single institution cohort study | Review of patient records | 21/31 | 10 (71) | 0 (0) | 4 (29) | Therapy data for SBC patients (4 patients had alkylating CTX) |
Alm El-Din 2009 [54] | USA | 1964-2001 | Single institution cohort study | Review of patient records | 21/31 | 130 (52) 24 (67) | 0 (0) 0 (0) | 118 (48) 12 (33) | First raw: therapy data for all patients (26% had alkylating CTX) Second raw: therapy data for SBC (22% had alkylating CTX) |
Hudson 1998 [29] | USA | 1968-1990 | Single institution | Review of patient records | 21/30 | 116 (30) | 15 (4) | 256 (66) | Therapy data of M + F HL patients |
Gervais-Fagnou 1999 [31] | Canada | 1965-1990 | Single institution cohort study (HL Dx. at ≤30y) | Review of patient records | 22/30 | 225 (55) | 0 (0) | 186 (45) | Therapy data of M + F HL patients |
Munker 1999 [32] | Germany | 1974-1994 | 6 institutions cohort study | Munich tumor registry, patient records, and patient & family contact | 24/31 | 484 (43.1) | 169 (15.1) | 464 (41.4) | Therapy data of M + F HL patients (8/9 SBC patients received RT) |
Green 2000 [34] | USA | 1960-1989 | Single institution cohort study (HL ≤20y at Dx.) | Patient records and mail contact | 24/30 | 1 (25) | 0 (0) | 3 (75) | Therapy data for SBC patients |
Swerdlow 2000 [36] | United Kingdom | 1963-1993 | BNLI (cohort study) | BNLI + 2 cancer databases | 24/31 | 1449 (27) | 1693 (31) | 2327 (42) | Therapy data of M + F HL patients (all SBC had RT) |
Swerdlow 2011 [62] | United Kingdom | 1963-2001 | BNLI (cohort study) | BNLI database (70 institutions) | 25/31 | 0 (0) | 2366 (41) | 3432 (59) | Therapy data of M + F HL patients (SBC: 14% CTX only, 86% CTX + RT) |
Cellai 2001 [38] | Italy | 1960-1991 | Single institution cohort study | Institutional patient records | 22/30 | 546 (36) | 325 (21) | 653 (43) | Therapy data of M + F HL patients (SBC patients: 6% RT, 94% RT + CTX) |
Neglia 2001 [39] | USA and Canada | 1970-1986 | 25 institutions (CCSS) cohort study (≤21y at HL Dx., 5-y survivors) | Institutional patient records | 26/32 | NR | NR | NR | Therapy data were reported for all children malignancies combined |
Kenney 2004 [45] | USA and Canada | 1970-1986 | Same as Neglia et al. [40] | Institutional patient records | 26/32 | NR | NR | NR | Therapy data were reported for all children malignancies combined |
Castellino 2011 [59] | USA and Canada | 1970-1986 | Institutional patient records | 26/32 | 263 (33) | 46 (6) | 472 (60) | Therapy data for all HL female patients | |
Foss Abrahamsen 2002 [40] | Norway | 1968-1985 | Single institution cohort study (HD ≥ 1y survivors) | National cancer registry | 21/30 | 447 (44) | 202 (20) | 363 (36) | Therapy data of M + F HL patients |
Bhatia 2003 [42] | USA and Europe | 1955-1986 | 15 institutions cohort study | Institutional patient records | 26/33 | 314 (23) 14 (47) | 106 (8) 0 (0) | 960 (69) 15 (53) | First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients |
Wahner-Roedler 2003 [44] | USA | 1950-1993 | Single institution cohort study | Institutional patient records | 23/31 | 322 (50) 23 (77) | 0 (0) 0 (0) | 327 (50) 7 (23) | First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients |
Behringer 2004 [60] | Germany | 1981-1989 | Multi-Institutional cohort study | German HL database | 23/31 | 675 (12.9) | 618 (11.8) | 3947 (75.3) | Therapy data of M + F HL patients |
Guibout 2005 [46] | UK and France | 1954-1985 | 8 institutions cohort study | Institutional patient records | 28/32 | 28 (23) | 9 (7) | 86 (70) | Therapy data of M + F HL patients |
Taylor 2007 [51] | UK | 1940-1991 | PBCS | National Registry of Childhood Tumors | 22/31 | 121 (37) 7 (44) | 63 (20) 0 (0) | 138 (43) 9 (56) | First raw: therapy data of female HL patients Second raw: therapy data of SBC patients |
USA | 1960-1990 | 5 institutions cohort study (<19y at HL Dx.) | Institutional patient records | 22/31 | 174 (44) 18 (62) | 37 (9) 3 (10) | 187 (47) 8 (28) | First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients | |
Howell 2009 [56] | UK | 1965-2008 | Cohort from a registry and single institution | Institutional patient records and a registry data | 27/31 | 6 (26) | 0 (0) | 17 (74) | Therapy data of SBC patients |
Inskip 2007 [61] | USA | 1973-2002 | PBCS (< 18y at Dx) | SEER database | 29/31 | NR | NR | NR |